Kairos Pharma, LTD. (KAPA) — 8-K Filings

All 8-K filings from Kairos Pharma, LTD.. Browse 22 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (22)

Kairos Pharma Announces Board & Executive Changes — Oct 15, 2025 Risk: medium
Kairos Pharma, LTD. announced on October 8, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure o
Kairos Pharma Enters Material Definitive Agreement — Oct 7, 2025 Risk: medium
On October 1, 2025, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
Kairos Pharma Files 8-K Report — Sep 18, 2025 Risk: low
On September 18, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
Kairos Pharma Files 8-K — Sep 11, 2025 Risk: low
On September 11, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
Kairos Pharma Files 8-K — Sep 3, 2025 Risk: low
Kairos Pharma, Ltd. filed an 8-K on September 3, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific m
Kairos Pharma Files 8-K: Other Events & Financials — Jul 15, 2025 Risk: medium
Kairos Pharma, Ltd. filed an 8-K on July 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific detail
Kairos Pharma Files 8-K: Material Agreement & Shareholder Vote — Jun 12, 2025 Risk: medium
On June 10, 2025, Kairos Pharma, Ltd. filed an 8-K report detailing a material definitive agreement, the submission of matters to a vote of security holders, an
Kairos Pharma Files 8-K — Jun 3, 2025 Risk: low
On June 3, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific
Kairos Pharma Appoints Marcum LLP as New Auditor — Apr 28, 2025 Risk: low
Kairos Pharma, Ltd. announced on April 23, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public acc
Kairos Pharma Files 8-K — Apr 24, 2025 Risk: low
On April 24, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specif
Kairos Pharma Files 8-K: Other Events & Exhibits — Mar 20, 2025 Risk: low
On March 20, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specif
Kairos Pharma Files 8-K Report — Feb 26, 2025 Risk: low
On February 26, 2025, Kairos Pharma, LTD. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits" without deta
Kairos Pharma Files 8-K: Other Events & Financials — Feb 6, 2025 Risk: low
On February 6, 2025, Kairos Pharma, LTD. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating u
Kairos Pharma Enters Material Agreement, Reports Equity Sales — Jan 17, 2025 Risk: medium
On January 16, 2025, Kairos Pharma, Ltd. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
Kairos Pharma Files 8-K on Agreements and Equity Sales — Jan 14, 2025 Risk: medium
On January 14, 2025, Kairos Pharma, Ltd. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial s
Kairos Pharma Files 8-K on Leadership Changes & Financials — Dec 13, 2024 Risk: medium
Kairos Pharma, LTD. filed an 8-K on December 13, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensa
Kairos Pharma Files 8-K — Nov 19, 2024 Risk: low
Kairos Pharma, LTD. filed an 8-K on November 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
Kairos Pharma Files 8-K Report — Oct 10, 2024 Risk: low
On October 9, 2024, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific f
Kairos Pharma Enters Material Definitive Agreement — Oct 4, 2024 Risk: medium
On October 1, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
Kairos Pharma Enters Material Definitive Agreement — Sep 27, 2024 Risk: medium
On September 23, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offi
Kairos Pharma Enters Material Definitive Agreement — Sep 24, 2024 Risk: medium
On September 20, 2024, Kairos Pharma, LTD. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offi
Kairos Pharma Enters Material Definitive Agreement — Sep 17, 2024 Risk: medium
On September 16, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its c

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX